A growing number of doctors prefer digital communications and the pharmaceutical industry is currently in the process of moving its sales force to a smaller structure that is more directly aligned with this new reality. One aspect of that change is the deployment of
This article reviews the study 'Examination of Online Direct-to-Consumer Prescription Drug Promotion' (FDA-2011-N-0230), which is designed to test different ways of presenting prescription drug risk and benefit information on branded drug Web sites.
This article includes insights on content marketing from pharma experts including Thibaud Guymard, Digital Marketing Manager at MSD France. Guymard has broad experience with pharma content marketing, including roles as co-creator of the Digital Health Think Tank and as an Advertising Manager at Saatchi & Saatchi Health. Guymard also assisted in developing the Pharma Content Marketing Webinar organized by Kakushin Webinars.
Pharma Promotional Spending in 2013: Professional Detailing, eDetailing, DTC Advertising, Professional Meetings, Journal Advertising
According to the latest Cegedim Strategic Data (CSD) Audit, the 20 pharma companies that spent the most on total promotion -- which includes traditional professional detailing, eDetailing, Direct-to-Consumer (DTC) advertising, professional meetings, and journal advertising -- spent a total of $14,784 Bn in 2013. This article analyzes data from several sources to determine how much of this is allocated to various media and channels and also looks at the trends for several channels.
This article is a review of the proposed FDA 'Experimental Study of Direct-to-Consumer Promotion Directed at Adolescents' (FR # FDA-2013-N-1151), which aims to assess how adolescents interpret drug risk in DTC advertising.
This article summarizes the social media accomplishments -- despite bumps in along the way -- that earned the Boehringer Ingelheim (BI) Global Social Media Team the coveted Pharmaguy Social Media Pioneer Award.
'The medical conference is dead, long live the medical conference,' is the title of a SlideShare presentation by Len Starnes (@lenstarnes), a respected digital health-care consultant. Starnes is referring to the emergence of the 'virtual' medical conference, which he believes will soon be adopted in one form or another by all medical societies. This article describes the changes occurring viz-a-viz major medical conferences and the impact this will have on the pharmaceutical industry, medical societies, healthcare professionals, and patients.
This reviews FDA's recommendations for distributing reprints that convey 'new risk information' for approved drugs.
A Public Affairs Specialist at FDA's Center for Drug Evaluation and Research (CDER) confirmed to several reporters that this guidance is actually PART of the long-awaited guidance that was promised after the November, 2009 public hearing and required by section 1121 of the Prescription Drug User Fee Act (PDUFA).
FDA intends to look for evidence that the 'major statement' of drug risks as currently implemented in DTC TV ads is often too long and 'may result in reduced consumer comprehension, minimization of important risk information and, potentially, therapeutic noncompliance due to fear of side effects.'